In Estonia, more than 200 000 HIV-tests are performed annually, and of these approximately 5-6% are within anonymous HIV testing sites. The percentage tested with rapid tests in anonymous testing sites has increased from 15% in 2010 to 53% in 2015. Furthermore, up to 65% of all newly diagnosed HIV-cases have been detected in these sites. The proportion of HIV-positive tests has decreased from 3.8% to 0.5% in anonymous testing sites and from 0.3% to 0.1% in general health care. Simultaneously, the cost of detecting one new HIV case has increased almost six times.
Introduction
Across Europe the number of people infected with HIV continues to rise, and the problem of late diagnosis has been described in many countries. In order to ensure timely diagnosis and access to care, it is recommended that HIV testing be provided in a wide range of settings, both medical and non-medical, and delivered by appropriately trained and competent staff [1] . Easily accessible, anonymous and free of charge community walk-in services have been found to be acceptable and convenient for people who are at higher risk of HIV infection [2] [3] [4] .
Estonia, located in North-Eastern Europe, has a total population of approximately 1.3 million people [5] and the highest rate of newly diagnosed HIV cases in European Union (20.6 cases per 100 000 population in 2015) [6] . HIV testing has been available since 1987 and has always been de-centralized. Besides testing in health care settings, a network of walk-in anonymous HIV counselling and testing sites (from here referred to as "testing sites") has been operating since 1988. Testing is provided by health care organizations and affiliated with local and regional hospitals. Services are financed by National Institute for Health Development (NIHD) from the state budget -they are free of charge for everybody, including undocumented migrants. In 2015, a total of 11 sites were operating all across the country, mostly in urban settings [7] .
Testing sites are staffed with specially trained nurses. They offer HIV testing and counselling as well as referrals to care for those who are newly HIV infected. Testing sites also organize community based testing in collaboration with local syringe exchange programs, drop-in centres for sex workers, gay-bars and saunas, and shelters.
In The objective of this analysis was to assess anonymous HIV testing in Estonia from 2005-2015, including the number of tests, the proportion found to be positive, and cost of testing.
Methods
We used:
(1) Programme data (including financial) collected by the testing sites (n = 11) and reported to NIHD monthly (only data regarding HIV testing were included in this study). Data are collected electronically, using Microsoft Office Excel or Open Office Excel. (2) Programme data on all HIV tests collected by laboratories (n = 33) that perform HIV testing and report to the Health Board annually. These data include anonymous testing data from testing sites as well as from private health care sites where people pay for anonymous testing. These data also include tests for blood and organ donors. Donations are screened with pooled PCR.
(3) HIV test price data from Estonian Health Insurance
Fund's price list [8] ; (4) HIV surveillance data from Health Board [9] .
Financial data from the testing sites include cost of tests, personnel and infrastructure. Financial data from general health care sites include only costs of tests (HIV testing is rarely provided as a single procedure and it is complicated to calculate the proportion of personnel and infrastructure costs that could be attributed to HIV testing). The exact price of pooled PCR test is not known. We assume that the price for testing 10 people with pooled PCR is equal to testing 10 people with the ELISA method. Thusly, the price of the ELISA method was used for calculating the costs of HIV testing in general health care. Costs do not include the cost of confirmatory testing.
Results Table 1 shows HIV testing data from testing sites and in general health care from 2005 to 2015. Every year, there are minor differences in the total numbers of anonymous tests in the two data sources. In general, it does not exceed a few thousand tests, which is 1-2% of all tests. Therefore, we have not deducted the number of anonymous tests conducted at testing sites from the total number of tests.
In Table 1 , the proportion of people who inject drugs (PWID) among new HIV cases in testing sites is also shown. Data on transmission route from the national HIV surveillance system has not been included because this data has only been collected as of 2010 and over the years the transmission route is unknown for 36-65% of new HIV cases [7] . Table 2 shows the annual budget of the testing sites, testing costs in general health care, and the cost of detection of one positive HIV case in both testing sites and general health care.
Results show that annually, more than 200 000 HIVtests were performed in Estonia, with approximately half among blood donors and pregnant women (data not shown) and approximately 5-6% in the testing sites. The percentage tested with rapid tests in testing sites has increased more than three times -from 15% in 2010 (n = 1583) to 53% in 2015 (n = 5892). At the same time, up to 65% of all new HIV cases were detected in testing sites. The positivity rate (proportion of conducted HIVtests that turn out to be positive) has decreased from 3.8% to 0.5% in testing sites and from 0.3% to 0.1% in general health care. The proportion of PWID among new HIV cases detected in testing sites has been more than halved (from 54% to 24%).
Discussion
From 2005 to 2015, the number of tests performed yearly in testing sites has increased almost two times, and the proportion of patients tested with rapid tests more than three times, suggesting that the services are well accepted by the general population as well as vulnerable populations. The reduction in the budget of the testing sites in 2009-2010 was related to the economic recession due to which the funding of NIHD was cut almost 40% [10] . Partly due to the donor support for introducing rapid testing, it was possible to continue testing on the same scale as before. The proportion of new HIV cases in Estonia detected at testing sites has been as high as 65% but has decreased in the recent years. This proportion might still be overestimated despite the change in reporting of new positive cases in 2009. For example, it is possible that some reactive rapid test results (since 2010) have been included as new HIV cases in spite of pending confirmation.
The positivity rate among those tested in testing sites remains higher than among all people tested, showing that the sites reach more of those who are at higher risk of HIV. One reason is that among all people tested, a large proportion is in groups not-at-risk, e.g. pregnant women and blood donors. However, the positivity rate in testing sites has decreased almost eight times within the study period. This may partly be due to the change in reporting of the positive cases -since 2009 only patients with a positive test who have no previous record of HIV-positive test in the reference laboratory's database are considered new HIV cases. Thus the number of new HIV cases since 2009 is more accurate. Another reason may be related to the change in the populations reached. In recent years, there have been several HIV testing promotional campaigns targeting the general population and testing events conducted in public places, where people with less risk of HIV might have attended testing. Also, the HIV incidence in Estonia is most likely decreasing -as witnessed by the decrease in the number of new cases, the decrease in the HIV incidence among new injectors and high knowledge of serostatus of people who inject drugs [7] . One of the main reasons for this could be expanded access to syringe exchange over the last 15 years [7, 11] .
As the positivity rate has decreased, the cost of detection of one new HIV case has increased (both in testing sites and general health care). The actual costs and the increase might be even higher, as the following costs items have not been taken into account:
(1) personnel and infrastructure costs in general health care -would increase the price of HIV tests in general health care; (2) confirmatory test costs -would increase the price of HIV tests in testing sites more than in general health care as testing sites have higher proportion of tests in need of confirmation; (3) rapid test costs -would increase the price in testing sites (these costs have not been included as they have been donated free of charge).
Cost of detection of one new HIV case has been cheaper in testing sites compared to general health care. Because of possible overestimation of the number of new HIV cases detected in testing sites and the discrepancy in the number of anonymous tests in two data sources (testing sites and general health care) we cannot estimate the true cost of detection of the new HIV case in general health care. We estimate that the difference in price would remain even after taking into account all the costs not included (listed above) and the overlap of the two data sources.
The proportion of PWID among new HIV cases in testing sites has been more than halved. Once again, this may be related to the change in reporting since 2009. However, research from other countries has shown that name-based reporting may not be as big of a barrier as sometimes feared [12, 13] . Undocumented data from our testing sites also confirms that only a few people refuse to provide personal data. Another explanation may be related to the change in the populations reached as described earlier. Another plausible reason could be the change in HIV transmission routes in Estonia in generalmore heterosexual cases have been reported in recent years, reflecting most likely the transition of HIV from PWID to their sexual partners and possibly the general population [7] .
Despite many limitations, this data can be used to monitor trends in anonymous testing outcomes. Monitoring of new HIV cases, re-testers and HIV transmission routes should be further improved.
In general, these outcomes suggest that anonymous testing has an important role in detecting new HIV cases in Estonia. In the future, testing sites should aim to better target people at higher risk of HIV.
